Two-pronged immune cell approach could lead to universal shot against flu

Seasonal epidemics of influenza result in nearly 36,000 deaths annually in the United States, according to the Centers for Disease Control. Current vaccines against the influenza virus elicit an antibody response specific for proteins on the outside of the virus, specifically the hemagglutinin (HA) protein.

Yearly vaccines are made by growing the in eggs. The viral envelope proteins, including HA, are cleaved off and used as the vaccine, but vary from year to year, depending on what are prevalent. However, high in envelope HA proteins result in the emergence of new viral types each year, which elude neutralization by preexisting antibodies in the body (specifically the HA proteins' specific receptor binding sites that are the targets of neutralizing antibodies). On the other hand, other immune cell types are capable of mediating protection through recognition of other, more conserved parts of HAs or highly conserved internal proteins in the influenza virus.

E. John Wherry, PhD, associate professor of Microbiology and director of the Institute for Immunology at the Perelman School of Medicine, University of Pennsylvania, and colleagues, report in PLOS Pathogens that -specific CD8+ T cells or virus-specific non-neutralizing antibodies are each relatively ineffective at conferring alone. But, when combined, the virus-specific CD8 T cells and non-neutralizing antibodies cooperatively elicit robust protective immunity.

This synergistic improvement in protective immunity is dependent, at least in part, on other —lung macrophages and phagocytes. An implication of this work is that immune responses targeting parts of the virus that are not highly variable can be combined for effective protection.

"The two-pronged approach is synergistic, so by enlisting two suboptimal vaccine approaches, we achieved a better effect than each alone in an experimental model," says Wherry. "Now, we are rethinking past approaches and looking for ways to combine T-cell vaccines and antibody vaccines to make a more effective combined vaccine."

"Overall, our studies suggest that an influenza vaccine capable of eliciting both CD8+ T cells and antibodies specific for highly conserved influenza proteins may be able to provide protection in humans, and act as the basis for a potential 'universal' vaccine," says Wherry.

These results suggest a novel strategy that could potentially form a primary component of a universal influenza vaccine capable of providing long-lasting protection.

Related Stories

New steps toward a universal flu vaccine

May 19, 2010

Researchers at Mt. Sinai School of Medicine have developed a novel influenza vaccine that could represent the next step towards a universal influenza vaccine eliminating the need for seasonal immunizations. They report their ...

Recommended for you

Growing a blood vessel in a week

Oct 24, 2014

The technology for creating new tissues from stem cells has taken a giant leap forward. Three tablespoons of blood are all that is needed to grow a brand new blood vessel in just seven days. This is shown ...

Testing time for stem cells

Oct 24, 2014

DefiniGEN is one of the first commercial opportunities to arise from Cambridge's expertise in stem cell research. Here, we look at some of the fundamental research that enables it to supply liver and pancreatic ...

Team finds key signaling pathway in cause of preeclampsia

Oct 23, 2014

A team of researchers led by a Wayne State University School of Medicine associate professor of obstetrics and gynecology has published findings that provide novel insight into the cause of preeclampsia, the leading cause ...

Rapid test to diagnose severe sepsis

Oct 23, 2014

A new test, developed by University of British Columbia researchers, could help physicians predict within an hour if a patient will develop severe sepsis so they can begin treatment immediately.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

jmlvu
not rated yet Mar 14, 2013
I took the flu shoot and as I lie here suffering from one of the strains left out of this years vacine, I wonder which WHO official was bribed by the pharma industry to leave my stain out.
You can bet congress gets the upgraded vacine.